After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...
“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...
It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...
Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on ...
“Should we have an RSV vaccine for older Australians? Absolutely. We have two highly effective vaccines, one made by GSK, one made by Pfizer, which are being implemented and used widely now in ...
With little fanfare, the Biden administration stacked a critical committee that helps set U.S. vaccination policy with new ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback